FCC ID: 2BA23-AGC1 The Atmo Gas Capsule is an ingestible gas-sensing device that periodically takes measurements within the human gastrointestinal tract. Measurements are transmitted wirelessly via radio frequency to a wearable Data Receiver.

BIOSCIENCES BIOSCIENCES Atmo Gas Capsule Atmo Biosciences Ltd wall 436 Elgar Rd, Box Hill, VIC 3128, Australia SN 3000001 oo 2022-07-18 REF! cAP010-0000US Ts wei lj ~ @ #?

@ wm FCC ID: 2BA23-AGC1 90%

Boonly 30%

Storage / Transport XY 45C/114F 10C/14F Storage/ Transport Brog97a79-1

(01) 9 3599210 00196 4 (11) 220718 (21) 3000001 Stock: Thermlfilm SELECT 21920

(White) Dimensions: 70mm x 88mm Corners: 3mm radius Powered by Adobe Acrobat Sign

Federal Communications Commission Authorization and Evaluation Division 7435 Oakland Mills Road Columbia, MD 21046 USA Date: 04-11-2024 Ref: Attestation Statements Part 2.911(d)(7) Filing - FCC ID: 2BA23-AGC1 Atmo Biosciences Ltd (the applicant) certifies that, as of the date of the filing of the application, Atmo Biosciences Inc. is our designated U.S. agent for service of process for the above referenced FCC ID. Atmo Biosciences Ltd accepts to maintain an agent for no less than one year after the grantee has terminated all marketing and importation or the conclusion of any Commission-related proceeding involving the equipment. Atmo Biosciences Inc. accepts, as of the date of the filing of the application, the obligation of the designated U.S. agent for service of process for the above referenced FCC ID. The agent for service of process does no other business with the FCC and does not have an FRN. Designated U.S. Agent Information:

Name:

Address:

Contact Person: Malcolm Hebblewhite Tel.:

Email:

Sincerely, Atmo Biosciences Inc. 3210 Merryfield Row, San Diego, California 92121, United States

+1 619 459 2600 mal.hebblewhite@atmobiosciences.com Atmo Biosciences Ltd Dr James John Head of R&D and Product Development James John Applicants FRN: 0033732827 Electronically signed by: James John Reason: Authorised Representative Date: Apr 11, 2024 13:16 GMT+10 Atmo Biosciences Inc. Malcolm Hebblewhite CEO Mal Hebblewhite Electronically signed by: Mal Hebblewhite Reason: Authorised Officer Date: Apr 11, 2024 12:35 GMT+10 Electronically signed by: James John Reason: Authorised Representative Date: Apr 11, 2024 13:16 GMT+10 James John james.john@atmobiosciences.com Head of R&D and Product Development Atmo Biosciences Ltd Signature:

Email:

Title:

Company:

Hebblewhite Reason: Authorised Officer Date: Apr 11, 2024 12:35 GMT+10 Mal Hebblewhite Electronically signed by: Mal mal.hebblewhite@atmobiosciences.com CEO Atmo Biosciences Ltd Signature:

Email:

Title:

Company:

Federal Communications Commission Authorization and Evaluation Division 7435 Oakland Mills Road Columbia, MD 21046 USA Date: 01-30-2024 Ref: Attestation Statements Part 2.911(d)(5)(i) Filing FCC ID: 2BA23-AGC1 Atmo Biosciences Ltd (the applicant) certifies that the equipment for which authorization is sought is not covered equipment prohibited from receiving an equipment authorization pursuant to section 2.903 of the FCC rules. Sincerely, Dr James John Head of R&D and Product Development Rev 1/26/2023 James JohnElectronically signed by: JamesJohnReason: Authorised RepresentativeDate: Feb 2, 2024 13:40 GMT+11

Federal Communications Commission Authorization and Evaluation Division 7435 Oakland Mills Road Columbia, MD 21046 USA Date: 02-19-2024 Ref: Attestation Statements Part 2.911(d)(5)(ii) Filing FCC ID: 2BA23-AGC1 Dr James John of Atmo Biosciences Ltd (the applicant) certifies that, as of the date of the filing of the application, the applicant is not identified on the Covered List as a specifically named entity or any of its subsidiaries or affiliates as an entity producing covered equipment. Sincerely, Electronically signed by: James John Reason: Authorised Representative Date: Feb 19, 2024 19:22 GMT+11 Dr James John Head of R&D and Product Development Rev 1/26/2023

Federal Communications Commission Authorization and Evaluation Division 7435 Oakland Mills Road Columbia, MD 21046 USA Date: 04-11-2024 Confidentiality Request regarding application for certification of FCC ID: 2BA23-AGC1. Pursuant to Sections 0.457 and 0.459 of the Commissions Rules, we hereby request confidential treatment of information accompanying this application as outlined below:

Exhibit Type Block Diagram Schematics Operational Description File Name CONF_2BA23-AGC1_Block Diagram.pdf CONF_2BA23-AGC1_Schematics Rev H.pdf CONF_2BA23-AGC1_Op Description.pdf The above materials contain trade secrets and proprietary information not customarily released to the public. The public disclosure of these materials may be harmful to the applicant and provide unjustified benefits to its competitors. The applicant understands that pursuant to Section 0.457 of the Rules, disclosure of this application and all accompanying documentation will not be made before the date of the Grant for this application. Pursuant to DA04-1705 June 15, 2004 of the Commissions public notice, we also request temporary confidential treatment of information accompanying this application as outlined below for a period of 180 days:

Exhibit Type User Manual External Photos Internal Photos Test Setup Photos File Name CONF_2BA23-AGC1_User Manual.pdf CONF_2BA23-AGC1_ExtPhotos.pdf CONF_2BA23-AGC1_IntPhotos.pdf CONF_2BA23-AGC1_TSetupPhotos.pdf Electronically signed by: James John Reason: Authorised Representative Date: Apr 11, 2024 13:17 GMT+10 James John Sincerely, Dr James John Head of R&D and Product Development Signature:

Email:

Title:

Company:

James John james.john@atmobiosciences.com Head of R&D and Product Development Atmo Biosciences Ltd Electronically signed by: James John Reason: Authorised Representative Date: Apr 11, 2024 13:17 GMT+10

ABN 82 057 105 549 EMC Technologies Pty. Ltd. Melbourne 176 Harrick Road Tel: +61 3 9365 1000 Keilor Park, Vic 3042 Web: www.emctech.com.au Tel: +61 2 9624 2777 Sydney Unit 3/87 Station Road Seven Hills, NSW 2147 Email: emc-general@emctech.com.au To Attention:

EMCT Ref:

Date:

Subject:

Federal Communications Commission Certification Officer M2303033 March 20, 2024 Atmo Biosciences Ltd Request for Original Certification (FCC ID: 2BA23-AGC1) Product Name:

Model:

FCC ID:

Radio:

Antenna:

Description:

Please Note:

Permanent Confidentiality:

Short-Term Confidentiality:

FCC ID, 15.19 statement FCC 15.105 Statement:

Agent:

Regards Atmo Gas Capsule System Capsule CAP010ZZ 2BA23-AGC1 Sub-1 GHz RF transceiver, Part Number S2-LPQTR Frequency: 433.870 MHz Custom Integrated Flex The Atmo Gas Capsule is an ingestible gas-sensing device that periodically takes measurements within the human gastrointestinal tract. Measurements are transmitted wirelessly via radio frequency to a wearable Data Receiver. Application includes request for permanent confidentiality Operational Description, Operational Description (Antenna), Block Diagram, Schematics Application includes request for short-term confidentiality 180 days Internal Photos, External Photos, Test Setup Photos, User Manual Application includes request to not label the device with the FCC ID and the 15.19 compliance statement. Refer to 13. Label Statement Exclusion Request.pdf Client has decided to omit section 15.105 (Information to the user) based on section 15.103 (Exempted devices) - specialized medical digital device (clause (e) of 15.103). EMC Technologies is acting as agent for Atmo Biosciences Ltd in this application. _____________ Shabbir Ahmed CEO EMC Technologies Pty Ltd 176 Harrick Road, Keilor Park, VIC 3042 Australia Ph: +61 3 9365 1000 www.emctech.com.au EMC Technologies Pty Ltd, 176 Harrick Road, Keilor Park VIC 3042 Australia www.emctech.com.au

F e d e r a l C o m m u n i c a t i o n s C o m m i s s i o n A u t h o r i z a t i o n a n d E v a l u a t i o n D i v i s i o n 7 4 3 5 O a k l a n d M i l l s R o a d C o l u m b i a

, M D 2 1 0 4 6 D a t e

0 4

1 6

2 0 2 4 S U B J E C T

F C C A p p l i c a t i o n f o r 2 B A 2 3

A G C 1 T o W h o m I t M a y C o n c e r n

W e

, t h e u n d e r s i g n e d

, h e r e b y a u t h o r i z e S h a b b i r A h m e d a t E M C T e c h n o l o g i e s P t y L t d t o a c t o n o u r b e h a l f

, t o a p p l y t o t h e F e d e r a l C o m m u n i c a t i o n s C o m m i s s i o n f o r F C C a p p r o v a l o f o u r e q u i p m e n t

. A n y a n d a l l a c t s c a r r i e d o u t b y S h a b b i r A h m e d a t E M C T e c h n o l o g i e s o n o u r b e h a l f s h a l l h a v e t h e s a m e e f f e c t a s a c t s o f o u r o w n

. T h i s i s t o a d v i s e t h a t w e a r e i n f u l l c o m p l i a n c e w i t h t h e A n t i

D r u g A b u s e A c t

. W e

, t h e a p p l i c a n t

, a r e n o t s u b j e c t t o a d e n i a l o f f e d e r a l b e n e f i t s p u r s u a n t t o S e c t i o n 5 3 0 1 o f t h e A n t i

D r u g A c t o f 1 9 8 8

, 2 1 U S C 8 5 3 a

, a n d n o p a r t y t o t h e a p p l i c a t i o n i s s u b j e c t t o a d e n i a l o f f e d e r a l b e n e f i t s p u r s u a n t t o t h a t s e c t i o n

. R e g a r d s

, D r J a m e s J o h n H e a d o f R

D a n d P r o d u c t D e v e l o p m e n t

0

w

w

w

4

w